Literature DB >> 27180984

Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach.

Quan Qi1,2, Rui Li1,2, Hui-Ying Li2, Yu-Bing Cao1, Ming Bai2, Xiao-Jing Fan3, Shu-Yan Wang4, Bo Zhang2,4, Shao Li2.   

Abstract

AIM: Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. In this study we used a network pharmacology approach to identify the anti-tumor activity of nuciferine and the underlying mechanisms.
METHODS: The pharmacological activities and mechanisms of nuciferine were identified through target profile prediction, clustering analysis and functional enrichment analysis using our traditional Chinese medicine (TCM) network pharmacology platform. The anti-tumor activity of nuciferine was validated by in vitro and in vivo experiments. The anti-tumor mechanisms of nuciferine were predicted through network target analysis and verified by in vitro experiments.
RESULTS: The nuciferine target profile was enriched with signaling pathways and biological functions, including "regulation of lipase activity", "response to nicotine" and "regulation of cell proliferation". Target profile clustering results suggested that nuciferine to exert anti-tumor effect. In experimental validation, nuciferine (0.8 mg/mL) markedly inhibited the viability of human neuroblastoma SY5Y cells and mouse colorectal cancer CT26 cells in vitro, and nuciferine (0.05 mg/mL) significantly suppressed the invasion of 6 cancer cell lines in vitro. Intraperitoneal injection of nuciferine (9.5 mg/mL, ip, 3 times a week for 3 weeks) significantly decreased the weight of SY5Y and CT26 tumor xenografts in nude mice. Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.
CONCLUSION: By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27180984      PMCID: PMC4933762          DOI: 10.1038/aps.2016.53

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  33 in total

Review 1.  Designing transient binding drugs: a new concept for drug discovery.

Authors:  Sten Ohlson
Journal:  Drug Discov Today       Date:  2008-03-18       Impact factor: 7.851

2.  Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group study.

Authors:  W A Knight; P Goodman; S A Taylor; J S Macdonald; C A Coltman; J J Constanzi; L H Baker
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

3.  Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents.

Authors:  Gary H Posner; Andrew J McRiner; Ik-Hyeon Paik; Surojit Sur; Kristina Borstnik; Suji Xie; Theresa A Shapiro; Adebusola Alagbala; Barbara Foster
Journal:  J Med Chem       Date:  2004-02-26       Impact factor: 7.446

4.  Free energy landscape for the binding process of Huperzine A to acetylcholinesterase.

Authors:  Fang Bai; Yechun Xu; Jing Chen; Qiufeng Liu; Junfeng Gu; Xicheng Wang; Jianpeng Ma; Honglin Li; José N Onuchic; Hualiang Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

5.  Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats.

Authors:  Yuka Ono; Eri Hattori; Yukitaka Fukaya; Shoji Imai; Yasushi Ohizumi
Journal:  J Ethnopharmacol       Date:  2006-02-21       Impact factor: 4.360

6.  Antioxidant activity of methanol extract of the lotus leaf (Nelumbo nucifera Gertn.).

Authors:  Ming-Jiuan Wu; Lisu Wang; Ching-Yi Weng; Jui-Hung Yen
Journal:  Am J Chin Med       Date:  2003       Impact factor: 4.667

7.  High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Authors:  Jon Pritchard; Simon J Cotterill; Shirley M Germond; John Imeson; Jan de Kraker; David R Jones
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167

8.  Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae.

Authors:  Shao Li; Bo Zhang; Duo Jiang; Yingying Wei; Ningbo Zhang
Journal:  BMC Bioinformatics       Date:  2010-12-14       Impact factor: 3.169

9.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders.

Authors:  Ada Hamosh; Alan F Scott; Joanna S Amberger; Carol A Bocchini; Victor A McKusick
Journal:  Nucleic Acids Res       Date:  2005-01-01       Impact factor: 16.971

10.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

View more
  18 in total

1.  A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.

Authors:  Dan-Dan Xiong; Yue Qin; Wen-Qing Xu; Rong-Quan He; Hua-Yu Wu; Dan-Min Wei; Jing-Jing Zeng; Yi-Wu Dang; Gang Chen
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

Review 2.  Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention.

Authors:  Anupam Bishayee; Palak A Patel; Priya Sharma; Shivani Thoutireddy; Niranjan Das
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.575

3.  Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease.

Authors:  Cheng-Jie Liang; Jia-Huang Li; Zhen Zhang; Ju-Yan Zhang; Shu-Qun Liu; Jie Yang
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

4.  Matrine Is Identified as a Novel Macropinocytosis Inducer by a Network Target Approach.

Authors:  Bo Zhang; Xin Wang; Yan Li; Min Wu; Shu-Yan Wang; Shao Li
Journal:  Front Pharmacol       Date:  2018-01-26       Impact factor: 5.810

5.  Nuciferine Ameliorates Inflammatory Responses by Inhibiting the TLR4-Mediated Pathway in Lipopolysaccharide-Induced Acute Lung Injury.

Authors:  Haichong Wu; Yaping Yang; Shuai Guo; Jing Yang; Kangfeng Jiang; Gan Zhao; Changwei Qiu; Ganzhen Deng
Journal:  Front Pharmacol       Date:  2017-12-21       Impact factor: 5.810

Review 6.  Benzylisoquinoline Alkaloids Biosynthesis in Sacred Lotus.

Authors:  Ivette M Menéndez-Perdomo; Peter J Facchini
Journal:  Molecules       Date:  2018-11-06       Impact factor: 4.411

7.  Network Pharmacology to Unveil the Biological Basis of Health-Strengthening Herbal Medicine in Cancer Treatment.

Authors:  Jiahui Zheng; Min Wu; Haiyan Wang; Shasha Li; Xin Wang; Yan Li; Dong Wang; Shao Li
Journal:  Cancers (Basel)       Date:  2018-11-21       Impact factor: 6.639

Review 8.  Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.

Authors:  Liu-Cheng Li; Lian-Di Kan
Journal:  J Ethnopharmacol       Date:  2016-12-28       Impact factor: 4.360

9.  Lotus leaf extract inhibits ER- breast cancer cell migration and metastasis.

Authors:  Yuelin Tong; Zhongwei Li; Yikuan Wu; Shenglong Zhu; Keke Lu; Zhao He
Journal:  Nutr Metab (Lond)       Date:  2021-02-18       Impact factor: 4.169

10.  Liensinine and Nuciferine, Bioactive Components of Nelumbo nucifera, Inhibit the Growth of Breast Cancer Cells and Breast Cancer-Associated Bone Loss.

Authors:  Eun Ji Kang; Sun Kyoung Lee; Kwang-Kyun Park; Seung Hwa Son; Ki Rim Kim; Won-Yoon Chung
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-03       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.